title: Comparison of endothelialization and neointimal formation with stents coated with antibodies against CD34 and vascular endothelial-cadherin.
abstract: Vascular endothelial-cadherin (VE-cadherin) is exclusively expressed on the late endothelial progenitor cells (EPC). Therefore, VE-cadherin could be an ideal target surface molecule to capture circulating late EPC. In the present study, we evaluated whether anti-VE-cadherin antibody-coated stents (VE-cad stents) might accelerate endothelial recovery and reduce neointimal formation more than anti-CD34 antibody-coated stents (CD34 stents) through the superior ability to capture the late EPC. The stainless steel stents were coated with anti-human VE-cadherin antibodies or anti-human CD34 antibodies under the same condition. In vitro, VE-cad stents showed higher number of adhering EPC (823.6 ± 182.2 versus 379.2 ± 137.2 cells per HPF, p < 0.001). VE-cad stents also demonstrated better specific capturing of cells with endothelial lineage markers than CD34 stents did in flow cytometric analysis. VE-cad stents showed more effective re-endothelialization after 1 h, 24 h, and 3 days in vivo. At 42 days, VE-cad stents demonstrated significantly smaller neointima area (0.92 ± 0.38 versus 1.24 ± 0.41 mm(2), p = 0.002) and significantly lower PCNA positive cells in neointima (1684.8 ± 658.8/mm(2) versus 2681.7 ± 375.1/mm(2), p = 0.008), compared with CD34 stents. In conclusion, VE-cad stents captured EPC and endothelial cells more selectively in vitro, accelerated re-endothelialization over stents, and reduced neointimal formation in vivo, compared with CD34 stents.
authors.affiliation: Innovative Research Institute for Cell Therapy, Seoul National University Hospital, Seoul, Republic of Korea.
authors.forename: Joo Myung
authors.initials: JM
authors.lastname: Lee
authors.forename: WonSeok
authors.initials: W
authors.lastname: Choe
authors.forename: Baek-Kyung
authors.initials: BK
authors.lastname: Kim
authors.forename: Won-Woo
authors.initials: WW
authors.lastname: Seo
authors.forename: Woo-Hyun
authors.initials: WH
authors.lastname: Lim
authors.forename: Chan-Koo
authors.initials: CK
authors.lastname: Kang
authors.forename: San
authors.initials: S
authors.lastname: Kyeong
authors.forename: Khee Dong
authors.initials: KD
authors.lastname: Eom
authors.forename: Hyun-Ju
authors.initials: HJ
authors.lastname: Cho
authors.forename: Young-Chan
authors.initials: YC
authors.lastname: Kim
authors.forename: Jin
authors.initials: J
authors.lastname: Hur
authors.forename: Han-Mo
authors.initials: HM
authors.lastname: Yang
authors.forename: Hyun-Jai
authors.initials: HJ
authors.lastname: Cho
authors.forename: Yoon-Sik
authors.initials: YS
authors.lastname: Lee
authors.forename: Hyo-Soo
authors.initials: HS
authors.lastname: Kim
mesh_terms: D000906:Antibodies / Q000737:chemistry*; D015703:Antigens, CD / Q000737:chemistry*; D018952:Antigens, CD34 / Q000737:chemistry*; D015820:Cadherins / Q000737:chemistry*; D049109:Cell Proliferation; D020099:Coated Materials, Biocompatible; D042783:Endothelial Cells / Q000166:cytology; D004727:Endothelium / Q000378:metabolism; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000737:chemistry; D058426:Neointima / Q000378:metabolism*; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism; D015607:Stents; D000099152:Cadherin 5
chemical_list: D000906:Antibodies; D015703:Antigens, CD; D018952:Antigens, CD34; D015820:Cadherins; D020099:Coated Materials, Biocompatible; D000099152:Cadherin 5